BOSTON, Oct 20- Billionaire investor William Ackman, whose fund is the largest shareholder in Allergan Inc., and Valeant Pharmaceuticals said the botox maker's Chief Executive Officer David Pyott tried to discredit Valeant as it was making a hostile takeover bid, court documents showed. Ackman's hedge fund has been working with Valeant for months to craft a...» Read More
LONDON, April 28- U.S. drugmaker Pfizer made a bid approach to AstraZeneca in January and contacted its British rival again on April 26 seeking to renew discussions about a takeover, the U.S. firm said on Monday. A Pfizer bid for AstraZeneca would be one of the largest ever pharmaceuticals deals.
April 27- German drugmaker Bayer AG is exploring the sale of its $10 billion plastics unit to focus on growing its health business, Bloomberg reported citing people with knowledge of the matter.
April 25- Prestige Brands Holdings Inc, a marketer and distributor of healthcare and cleaning products, said it would buy rival Insight Pharmaceuticals Corp for $750 million in cash to expand its range of feminine care products.
Nicholas Heyman, William Blair, discusses General Electric's possible acquisition of French train and power plant builder Alstom for more than $13 billion.
Sandy Villere, Villere Funds, shares his thoughts on Greenlight Capital's new stake in Conn's.
Eli Lilly Chairman & CEO John Lechleiter discusses his business' expansion of its animal health unit with the acquisition of Novartis' animal health business.
GlaxoSmithKline CEO Sir Andrew Witty, explains the large portfolio of vaccinations his company provides, and the value added from the company's acquisition of Novartis' vaccination business.
GlaxoSmithKline CEO Sir Andrew Witty, discusses the benefit to shareholders from his company's acquisition of Novartis' vaccination business, as well as its oncology unit.
Bob Moritz, PricewaterhouseCoopers chairman and senior partner, discusses the company's plan to boost its consulting business by extending its global reach.
Arne Sorenson, CEO & president of Marriott International, discusses his company's acquisition of the largest hotel company in Africa.
Michael Carr, Goldman Sachs M&A group in the Americas, shares his thoughts on the role of activists in deal making and the outlook for mergers and acquisitions.
Activism in the long-term is not only bad for shareholders but also bad for the economy as a whole, says Martin Lipton, Wachtell, Lipton, Rosen & Katz, expressing his views on shareholder activism. Also Lipton shares his thoughts on the two categories of hedge fund activism.
It's been a robust 12 months of mergers and buyouts. Here's an inside look at four high-profile deals from Facebook-WhatsApp to Warren Buffett's involvement with Heinz.
Discussing Facebook's decision to purchase virtual reality technology company Oculus VR for $2 billion, with Dennis Berman, The Wall Street Journal.
Discussing Facebook's decision to purchase virtual reality technology company Oculus for $2 billion, with Mike Isaac, Re/code senior editor.
Facebook purchased virtual reality technology company Oculus for $2 billion. Stephan Paterno, Slated CEO & co-founder, says Mark Zuckerberg is making an "offensive bet."
Facebook purchased virtual reality technology company Oculus for $2 billion, reports CNBC's Josh Lipton.
Facebook purchased virtual reality technology company Oculus for $2 billion just five weeks after announcing a $16 billion deal to buy WhatsApp, reports CNBC's Josh Lipton. The FMHR traders provide perspective.
Facebook acquired virtual reality technology company Oculus for $2 billion. John McDuling of Quartz thinks the Oculus acquisition is more ambitious than the WhatsApp purchase.
The social media giant is getting into the virtual reality game, reports CNBC's Jon Fortt with details of the deal and a look at how Oculus works.